These 3 Aussie stocks could skyrocket and stay there for decades

Let's see what sets these stocks apart from the rest.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • CSL Ltd, a biotechnology leader with a robust plasma collection network and extensive R&D investment, offers high barriers to entry and future growth prospects despite recent share price pressure.
  • Pro Medicus, known for its Visage medical imaging platform, enjoys high margins and growth potential with sticky recurring revenues from long-term U.S. contracts, positioned to benefit from global healthcare digitization.
  • WiseTech Global, with its indispensable CargoWise platform in logistics, maintains a dominant market position with high switching costs and is poised for long-term growth through global trade expansion and strategic acquisitions.

Every now and then, the ASX delivers stocks with the potential not only to climb higher but to keep delivering for shareholders long after the initial run-up.

These are the kinds of businesses with strong competitive advantages, huge global markets, and management teams that know how to execute.

Let's now look at three Aussie stocks that tick these boxes and could be destined to skyrocket — and stay there for decades.

A woman wearing dark clothing and sporting a few tattoos and piercings holds a phone and a takeaway coffee cup as she strolls under the Sydney Harbour Bridge which looms in the background.

Image source: Getty Images

CSL Ltd (ASX: CSL)

CSL is a biotechnology giant that has turned into one of Australia's greatest corporate success stories. With its plasma therapies, vaccines, and specialty treatments, this Aussie stock has built a global footprint that few rivals can match.

What makes CSL so attractive for long-term investors is its moat. The company operates one of the world's largest plasma collection networks and reinvests heavily into research and development each year. This combination creates high barriers to entry and a pipeline of new treatments to fuel future growth.

While its share price has been under pressure recently, history suggests that CSL has the resilience and the innovation to keep compounding earnings well into the future.

Pro Medicus Ltd (ASX: PME)

Another Aussie stock to look at is Pro Medicus. It is a medical imaging software provider that's taking the healthcare world by storm. Its Visage platform allows hospitals and radiologists to view, share, and analyse images faster and more efficiently than traditional systems.

Once installed, Visage generates sticky recurring revenues from long-term contracts, particularly in the U.S. healthcare system. With major hospitals already on board and new deals being signed, Pro Medicus has plenty of room to grow.

Its margins are among the best on the ASX, and with the digitisation of healthcare accelerating globally, Pro Medicus could remain a top performer for decades.

WiseTech Global Ltd (ASX: WTC)

Finally, WiseTech Global has become an indispensable player in the logistics industry. The Aussie stock's CargoWise platform is used worldwide by freight forwarders, customs brokers, and transport companies to manage supply chains.

The company has carved out a dominant position by offering a single, integrated solution that replaces clunky, outdated systems. Its customer base is sticky, with high switching costs that make it difficult for rivals to compete.

With global trade volumes expected to keep rising and WiseTech expanding its product suite with acquisitions, its long-term growth potential is enormous. For investors, it could be a classic example of an ASX tech company with global scalability.

Motley Fool contributor James Mickleboro has positions in CSL, Pro Medicus, and WiseTech Global. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and WiseTech Global. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool Australia has recommended CSL and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Woman laying with $100 notes around her, symbolising dividends.
Growth Shares

Where to invest $20,000 in ASX 200 shares in August

I would look for businesses that can keep expanding beyond their current markets.

Read more »

Rising arrow on a blue graph symbolising a rising share price.
Growth Shares

2 ASX 200 shares I rate as top buys for growth

I reckon these stocks offer significant potential.

Read more »

Cheerful boyfriend showing mobile phone to girlfriend with a coffee mug in dining room.
Growth Shares

3 ASX growth shares I'd buy with $10,000 today

These companies still have plenty to prove, but their long-term growth opportunities look attractive to me.

Read more »

A montage of planes, ships, and trucks.
Growth Shares

WiseTech buys FRDM.ai. What does this mean for WiseTech shares?

A small deal with a big strategic idea attached.

Read more »

A woman with a magnifying glass adjusts her glasses as she holds the glass to her computer screen and peers closely at it.
Growth Shares

3 growing ASX shares I'd buy and hold for 10 years

I think these growing ASX shares have the kind of platforms that could become much more valuable over time.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Growth Shares

Should I invest $5,000 into Goodman Group shares?

This is not a cheap ASX share, but the data centre opportunity keeps me interested.

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Growth Shares

3 ASX 200 shares down over 30% that I'd buy

The market has turned cautious on these shares, but I still see long-term growth potential.

Read more »

A stopwatch ticking close to the 12 where the words on the face say 'Time to Buy'.
Growth Shares

2 top ASX shares to buy and hold for the next decade

I’d own these businesses for the next decade or more…

Read more »